We therefore performed an open-label single-arm two step phase 2 study to investigate the potential clinical activity and safety of lapatinib in advanced breast cancer patients with HER2 non-amplified primary tumors with EGFR positive CTCs, thereby attempting to expand treatment options in patients who would not normally be considered for these therapies. Here, ERBB2 is linked to breast cancer.